Compare Incyte Corporation (INCY) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Monolithic Power Systems Inc — how do they compare? Incyte Corporation trades at $117.76 (market cap $23.11B), while Monolithic Power Systems Inc trades at $1,372.57 (market cap $65.28B). The key difference: Monolithic Power Systems Inc is far larger — about 2.8× Incyte Corporation's market cap, and Monolithic Power Systems Inc pays a 0.6% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MPWR | |
|---|---|---|
Market Cap | $23.11B | $65.28B |
Sector | Health | Utilities |
52-Week High | $118.52 | $1.69K |
52-Week Low | $67.38 | $711.24 |
Enterprise Value | $19.13B | $63.94B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MPWR trades at $1,328.80, up 1.28% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 22.98% net margin and robust cash flow, but carries high valuation multiples like a P/E of 93.92. Analyst consensus is overwhelmingly bullish with an $1,810 price target, though news includes both AI infrastructure optimism and legal investigations.
Outlook remains positive given earnings momentum and AI-driven demand, but risks include stretched valuations and ongoing legal scrutiny. The stock offers growth exposure but requires monitoring of execution and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
